Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

A nasal spray vaccine that puts your immune system on permanent high alert – and could one day protect against flu, COVID and future pandemics.

Moderna’s stock was surging after the FDA said it would review the biotech’s flu-vaccine candidate, a week after it had refused to do so.

HANGZHOU, China, Feb. 9, 2026 /PRNewswire/ -- Zhejiang Difference Biological Technology Co., Ltd. (DIFF Biotech) announced that its proprietary nasal spray influenza attenuated live vaccine, DIFF-flu, ...

In an early animal test, a new nasal-spray vaccine has shown promise against a variety of germs and a common allergen, ...

Unlike traditional systemic vaccines, the mRNA vaccine under evaluation is designed to trigger a robust immune response directly at the site of influenza entry, with potential to reduce viral ...

When Tiba Biotech was included in the cancellation of $500 million worth of grants funding mRNA vaccine development, the company was shocked. That’s because Tiba’s project doesn’t use mRNA and is not ...

Add Yahoo as a preferred source to see more of our stories on Google. A biotech company in New York is testing out a fentanyl vaccine that, if effective, could completely upend overdose prevention and ...

Arbutus alleges that Moderna’s COVID-19 vaccine infringes on patents protecting its lipid nanoparticle delivery technology.

Merck & Co. is turning down its option to license Evaxion’s gonorrhea vaccine candidate, closing the door on the Danish biotech’s chance to collect up to $592 million in biobucks. Evaxion will now ...